<qa>  What is the name of the Swedish patients with SpAAS?1 Describe the characteristics of Swedish patients with inflammatory SpAAS ; 2 Describe the use of etoricoxib and other cyclooxygenase-2 COX-2 inhibitorsnon-selective nonsteroidal anti-inflammatory drugs nsNSAIDs in Swedish patients with SpAAS; and 3 Estimate and compare the rates of clinical outcomes of special interest gastrointestinal, renovascular, cardiovascular and cerebrovascular with use of etoricoxib and other COX-2 inhibitorsnsNSAIDs in Swedish patients with SpAAS. Comparisons of clinical outcomes among the drugs of interest will be made by descriptive comparison of the point estimates for the incidence rates and their associated 95 confidence intervals CIs, using both clinical and epidemiological judgment and in light of the limitations of this observational study. No formal statistical significance testing will be performed for purposes of such comparisons. 